Pliant Therapeutics, Inc.
General ticker "PLRX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $255.0M (TTM average)
Pliant Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -2.5%.
Estimated limits based on current volatility of 6.5%: low 1.39$, high 1.58$
Factors to consider:
- Total employees count: 171 (+8.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Product liability, Acquisition/divestiture risks, Data protection
- Current price 81.9% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.25$, 19.15$]
- 2025-12-31 to 2026-12-31 estimated range: [6.09$, 16.43$]
Financial Metrics affecting the PLRX estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.12 <= 0.33
- Positive: Interest expense per share per price, % of 0.37 <= 0.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 76.60 > 63.39
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PLRX quotes
Long-term PLRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $9.69MM | $1.58MM | $0.00MM |
| Operating Expenses | $136.88MM | $185.72MM | $228.37MM |
| Operating Income | $-127.20MM | $-184.15MM | $-228.37MM |
| Non-Operating Income | $3.88MM | $22.81MM | $18.06MM |
| Interest Expense | $0.79MM | $1.27MM | $3.02MM |
| R&D Expense | $96.94MM | $127.80MM | $169.31MM |
| Income(Loss) | $-123.32MM | $-161.34MM | $-210.30MM |
| Profit(Loss)* | $-123.32MM | $-161.34MM | $-210.30MM |
| Stockholders Equity | $313.34MM | $473.58MM | $304.08MM |
| Assets | $350.61MM | $512.15MM | $396.95MM |
| Operating Cash Flow | $-94.63MM | $-116.36MM | $-155.50MM |
| Capital expenditure | $1.76MM | $0.92MM | $3.85MM |
| Investing Cash Flow | $-150.20MM | $-127.01MM | $140.34MM |
| Financing Cash Flow | $226.85MM | $274.40MM | $23.12MM |
| Earnings Per Share** | $-2.94 | $-2.75 | $-3.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.